Efficacy and clinical management of buprenorphine;Eficacia y manejo clínico de la buprenorfina

Trastornos Adictivos

Volumn 10, Issue 2, 2008, Pages 77-87

  Roncero Alonso, C ^a,b,c   Saez Francas N ^c   Castells, X ^c   Casas, M ^b  

^a Centro de Atención Y Seguimiento de Drogodependencias Vall d'Hebron   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Buprenorphine; Clinical utility; Efficacy; Opiate dependence

Indexed keywords

ALCOHOL; BENZODIAZEPINE; BUPRENORPHINE; CARBAMAZEPINE; DESIPRAMINE; DIAMORPHINE; FLUVOXAMINE; INDINAVIR; KETOCONAZOLE; LEVACETYLMETHADOL; METHADONE; MORPHINE; NALOXONE; NALTREXONE; OMEPRAZOLE; PLACEBO; RITONAVIR;

COMORBIDITY; DETOXIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAINTENANCE THERAPY; OPIATE ADDICTION; REVIEW;

EID: 47649113587     PISSN: 15750973     EISSN: 15782638     Source Type: Journal    
DOI: 10.1016/S1575-0973(08)74549-5     Document Type: Review

References (82)

1. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov. 2002;1:710-26.
2. Roncero C, Casas M. Eficacia clínica de la buprenorfina. Trastornos adictivos. 2005;7:23-6.
3. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40:17-25.
4. Krook AL, Brors O, Dahlberg J, Grouff K, Magnus P, Roysamb E, et al. A placebo controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97:533-42.
5. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Buprenorphine/Naloxone Collaborative Study Group. Office based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-58.
6. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662-8.
7. Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004;99:1439-49.
8. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomised clinical trial. Addiction. 1998;93:475-86.
9. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;(3):CD002207.
10. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70(2 Suppl) :S49-57.
11. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-5.
12. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358-64.
13. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025-30.
14. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401-7.
15. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713-20.
16. Uehlinger C, Deglon JJ, Livoti S, Petitjean S, Waldvogel D, Ladewin D. Comparison of buprenorphine and methadone in the treatment of the opioid dependence. Eur Addict Res. 1998;4:13-8.
17. Pani PP, Maremmani J, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39-50.
18. Amass L, Kamien JB, Branstetter SA, Mikulich SK. A controlled comparison of the buprenorphine-naloxone tablet and methadone for opioid maintenance treatment intern results. En: Harvis LS, editor. Problems of drug dependence. NIDA Research Monograph. Washintong DC: US Government Printing Office; 2000.
19. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadil acetate, buprenorphine and methadone for opioid dependence. N Engl J Med. 2000;343:1290-7.
20. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin dependent outpatients. J Subst Abuse Treat. 2003;24:217-20.
21. Mattick PP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441-52.
22. Kristensen O, Espegren O, Asland R, Jakobsen E, Lie O, Seiler S. Buprenorphine and methadone to opiate addicts: a randomized trial. Tidsskr Nor Laegeforen. 2005;125:148-51.
23. Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend. 1999;56:191-203.
24. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55:139-46.
25. Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33:91-8.
26. Gerra G, Borella F, Zaimovic A, Moi G, Bussamdri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75:37-45.
27. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Hinterhuber H, Kurz M. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98:693-702.
28. Giacomuzzi S, Yvonne R. Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients. Forensic Sci Int. 2005;152:323-4.
29. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev. 2003;(4):CD003410.
30. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004;73:219-26.
31. Marsh LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62:1157-64.
32. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend. 2005;77:71-9.
33. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2002;(2): CD002025.
34. Ebner R, Schreiber W, Zierer C. Buprenorphine or methadone for detoxification of young opioid addicts? Psychiatr Prax. 2004;31 Suppl 1:S108-10.
35. Seifert J, Metzner C, Paetzold W, Borsutzky M, Paissie T, Rollnik J, et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry. 2002;35:159-64.
36. Seifert J, Metzner C, Paetzold W, Borsutzky M, Ohlmeier M, Passie T, et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addict Biol. 2005;10:157-64.
37. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004;75:34-48.
38. Schottenfeld R, Chawarski M, Pakes JR, Pantalon M, Carroll K, Kosten TR. Methadone vs buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005;162:340-9.
39. Montoya ID, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, et al. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat. 2005;28:247-54.
40. Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 1999;56:812-20.
41. Emrich HM, Vogt P, Herz A. Passible antidepressant effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 1982;398:108-12.
42. Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7:51-4.
43. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharm. 1995;15:49-57.
44. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine versus methadone maintained patients. J Nerv Ment Dis 1998;186:35-43.
45. Gerra G, Leonardi C, D'Amore A, Strepparola G, Fagetti R, Assi C, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:265-72.
46. Dean AJ, Bell J, Christie MJ, Mattick R. Depressive symptoms during buprenorphine versus methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19:510-3.
47. Schmauss CL, Alexander MB, Yassousidis. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340-2.
48. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12:379-84.
49. O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, et al. A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse. 1996;22:523-31.
50. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment. Drug Alcohol Depend. 2005;79:113-6.
51. Pérez de los Cobos J, Martín S, Etcheberrigaray A, Trujols J, Batlle F, Tejero A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend. 2000;59:223-33.
52. Schottenfeld RS, Pakes J, O'Connor P, Chewarski M, Oliveto A, Kosten TR. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000;47:1072-9.
53. Marsch LA, Bickel W, Badger G, Jacobs EA. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 2005;77:195-204.
54. Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004;99:1439-49.
55. Chawarski M, Moody DE, Pakes J, O'Connor P, Schottenfeld RS. Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat. 2005;29:307-12.
56. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction. 2007;102:1648-56.
57. Jones HE, Johnson RE, Jasinki DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10.
58. Lange WR, Fudala PJ, Johnson RE. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 1990;26:19-28.
59. Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol. 2004;24:479-87.
60. a ed. Barcelona: Masson; 2004. p. 2158-70.
61. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy. 2005;25:611-4.
62. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002;35:513-6.
63. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96:267-72.
64. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. Am J Psychiatry. 2004;13 Suppl 1:S17-28.
65. Álvarez FJ. El coste del tratamiento con buprenorfina en los pacientes dependientes de opiáceos. Gastar 4 millones de euros o dejar que mueran 8 pacientes. Conductas Adictivas. 2004;4:1-2.
66. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol. 2005;25:490-3.
67. Álvarez FJ, González-Saíz F, Meana JJ, Pineda J, Roncero C. Documento de consenso de la Sociedad Española de Toxicomanías sobre el empleo y la disponibilidad de la buprenorfina para el tratamiento de la dependencia de opiáceos en España. Trastornos Adictivos. 2005;7:44-6.
68. Doran CM, Sanan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003;71:295-302.
69. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative in a primary care setting. Pharmacoeconomics. 2005;23:77-91.
70. West SL, O'Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse. 2000;12:405-14.
71. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96:683-90.
72. Iruín A, Aizpurua I, Ruiz de Apodaka J, Zapiraín E, Aizpuru A. Review of scientific evidence on alternatives to methadone in the psychopharmacologic treatment of opiate dependence. Rev Esp Salud Publica. 2001;75:207-19.
73. Farré M, Mas A, Torrens M, Moreno V, Camí J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002;65:283-90.
74. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2004;(4):CD005031.
75. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2002;(4):CD002207. Review. Update in: Cochrane Database Syst Rev. 2003;(2): CD002207.
76. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002207. Review. Update in: Cochrane Database Syst Rev. 2004;(3): CD002207.
77. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002025. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD002025.
78. Sung S, Conry JM. Role of buprenorphine in the management of heroin addiction. Ann Pharmacother. 2006;40:501-5.
79. Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51:635-46.
80. Baño Rodrigo MD. Tratamiento de sustitución con buprenorfina (Subutex®): modelo de aplicación de una experiencia piloto en la Comunidad de Madrid. Trastornos Adictivos. 2003;5:303-8.
81. García Cabeza A, González Rodríguez A. Uso de buprenorfina en la desintoxicación del mantenimiento con metadona. Trastornos Adictivos. 2003;5:303-8.
82. González-Saiz F, Gutiérrez Ortega J, Bilbao Acedos J, Ballesta Gómez R, Lozano Rojas O. Inducción a buprenorfina sublingual desde metadona: estudio clínico descriptivo en una muestra de pacientes tratados en una comunidad terapéutica. Trastornos Adictivos. 2008;10:49-64.